NEW YORK, NY, USA I October 22, 2024 I SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into ...

PRINCETON, NJ, USA & TOKYO, Japan I2, 2024 I Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd.

AACHEN, Germany I October 22, 2024 I Today, Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for ...

ROCKVILLE, MD & DEERFIELD, IL, USA I2, 2024 I MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, ...

ROCKVILLE, MD, USA I October 21, 2024 I REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the ...

BAGSVAERD, Denmark I1, 2024 I Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, ...

VANCOUVER, Canada I1, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...

MONTREAL, Canada I1, 2024 I Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies ...

The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with DME ...

SOUTH SAN FRANCISCO, CA, USA I October 17, 2024 I Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative ...

CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. (“Baiyu”) today announced that it has entered into an exclusive license agreement with Novartis for a small molecule ...

-ATX-01 is the industry’s first anti-microRNA therapeutic to be investigated in DM1 – VALENCIA, Spain I October 18, 2024 I ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on ...